Occurrence and impact of unanticipated variation in intravenous methotrexate dosing

Annals of Pharmacotherapy

Volumn 40, Issue 5, 2006, Pages 805-811

  Parshuram, Christopher S ^a,b,c,d,e   Dupuis, L Lee ^e   To, Teresa ^b,c,f,g   Weltzman, Sheila S ^c,e   Koren, Gideon ^c,e   Laupacis, Andreas ^f,h  

^a Department of Critical Care Medicine ^*  (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ONTARIO MINISTRY OF HEALTH AND LONG TERM CARE   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g MINISTRY OF HEALTH   (Canada)

^h Institute of Clinical and Evaluative Sciences   (Canada)

Author keywords

Adverse drug event; Medication error; Methotrexate

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; LIVER ENZYME; METHOTREXATE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE LYMPHOBLASTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG INFUSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MEDICATION ERRORS; METHOTREXATE; PROSPECTIVE STUDIES;

EID: 33646765344     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G334     Document Type: Article

References (29)

1. Parshuram CS, Ng G, Ho T, et al. Discrepancies between ordered and delivered concentrations of opiate infusions in critical care. Crit Care Med 2003;31:2483-7.
2. Ferner RE, Langford NJ, Anton C, Hutchings A, Bateman DN, Routledge PA. Random and systematic medication errors in routine clinical practice: a multicentre study of infusions, using acetylcysteine as an example. Br J Clin Pharmacol 2001;52:573-7.
3. Allen-Webb EM, Ross MP, Pappas JB, McGough EC, Banner W Jr. Age-related amrinone pharmacokinetics in a pediatric population. Crit Care Med 1994;22:1016-24.
4. Allen EM, Van Boerum DH, Olsen AF, Dean JM. Difference between the measured and ordered dose of catecholamine infusions. Ann Pharmacother 1995;29:1095-100.
5. Buclin T, Perrottet N, Biollaz J. The importance of assessing the dose actually administered in pharmacokinetic trials. Clin Pharmacol Ther 2005;77:235-40.
6. Richards CF, Cannon CP. Reducing medication errors: potential benefits of bolus thrombolytic agents. Acad Emerg Med 2000;7:1285-9.
7. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 1986;314:471-7.
8. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977;297:630-4.
9. Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol 1979;3:161-6.
10. Crom WR, Evans WE. Methotrexate. In: Evans WE, Jusko WJ, eds. Applied clinical pharmacokinetics. 3rd ed. Vancouver, WA: Applied Therapeutics Inc., 1992:29.1-29.42.
11. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338:499-505.
12. Pharmacy Discipline Committee. Pharmacology Manual. 3rd ed. Arcadia, CA: Childrens Oncology Group, 2003:119-23.
13. Murry DJ, Synold TW, Pui CH, Rodman JH. Renal function and methotrexate clearance in children with newly diagnosed leukemia. Pharmacotherapy 1995;15:144-9.
14. Crom WR, Glynn AM, Abromowitch M, Pui CH, Dodge R, Evans WE. Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance. Clin Pharmacol Ther 1986;39:592-7.
15. Cash M, Schafhauser B, Byers JF. Venipuncture versus central venous access: a comparison of methotrexate levels in pediatric leukemia patients. J Pediatr Oncol Nurs 1999;16:189-93.
16. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987;34:571-90.
17. Skinner R, Cole M, Pearson AD, et al. Inaccuracy of glomerular filtration rate estimation from height/plasma creatinine ratio. Arch Dis Child 1994;70:387-90.
18. Joannon P, Oviedo I, Campbell M, Tordecilla J. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer 2004;43:17-22.
19. Koskelo EK, Saarinen UM, Siimes MA. Skeletal muscle wasting and protein-energy malnutrition in children with a newly diagnosed acute leukemia. Cancer 1990;66:373-6.
20. Sala A, Tarnopolsky M, Webber C, Norman G, Barr R. Serum creatinine: a surrogate measurement of lean body mass in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2005;45:16-9.
21. Nahata MC. Paediatric drug therapy. II-Drug administration errors. J Clin Pharm Ther 1988;13:399-402.
22. Nahata MC, Crist KD. Comparison of two infusion methods for pharmacokinetic monitoring of gentamicin. Ther Drug Monit 1990;12:150-3.
23. Errick JK, Torre MS, Coleman JB, Hryciuk FL. Pharmacokinetic considerations of variation in intermittent infusion time duration. Clin Pharm 1982;1:61-2.
24. Sackett DL. Clinical epidemiology: a basic science for clinical medicine. 2nd ed. Boston, MA: Little Brown and Company, 1991:183.
25. Sand TE, Jacobsen S. Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol 1981;19:453-6.
26. Sasaki K, Tanaka J, Fujimoto T. Theoretically required urinary flow during high-dose methotrexate infusion. Cancer Chemother Pharmacol 1984;13:9-13.
27. Christensen ML, Rivera GK, Crom WR, Hancock ML, Evans WE. Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia. J Clin Oncol 1988;6:797-801.
28. Kinoshita A, Kurosawa Y, Kondoh K, et al. Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2003;51:256-60.
29. Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001;285:2114-20.